Hedwig M Blommestein (H M Blommestein, Hedwig Blommestein)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 12

Top Topics

Replacement Therapy

Multiple Myeloma

Top Venues

European journal of haematology

Journal of the National Cancer Institute

Expert review of anticancer therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Marianne Luyendijk, Agnes Jager, Sanne M Buijs, Sabine Siesling, Carin A Uyl-de Groot, Hedwig M Blommestein
Cost-Effectiveness Analysis of MammaPrint ® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer. PharmacoEconomics (2023)
Brenda Leeneman, Hedwig M Blommestein, Annemieke van Dongen-Leunis, Mattia Algeri, Willem E Fibbe, Liesbeth Oosten, Carin A Uyl-de Groot, Frederick W Thielen
Health-related quality of life in patients with steroid-refractory acute graft-versus-host disease. European journal of haematology (2023)
Marianne Luyendijk, Otto Visser, Hedwig M Blommestein, Ignace H J T de Hingh, Frank J P Hoebers, Agnes Jager, Gabe S Sonke, Elisabeth G E de Vries, Carin A Uyl-de Groot, Sabine Siesling
Changes in survival in de novo metastatic cancer in an era of new medicines. Journal of the National Cancer Institute (2023)
Yi Hsuan Chen, Hedwig M Blommestein, Reinder Klazenga, Carin Uyl-de Groot, Marco van Vulpen
Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands. Cancers 15 (2) (2023)
Yi Hsuan Chen, Hedwig M Blommestein, Reinder Klazenga, Carin Uyl-de Groot, Marco van Vulpen
Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands. Cancers 15 (2) (2023)
Maarten R Seefat, David G J Cucchi, K Groen, M L Donker, K G van der Hem, M Westerman, A M Gerrits, A Beeker, Niels W C J van de Donk, Hedwig M Blommestein, Sonja Zweegman
Treatment sequences and drug costs from diagnosis to death in multiple myeloma. European journal of haematology (2023)
Yi Hsuan Chen, Hedwig M Blommestein, Reinder Klazenga, Carin Uyl-de Groot, Marco van Vulpen
Costs of Newly Funded Proton Therapy Using Time-Driven Activity-Based Costing in The Netherlands. Cancers 15 (2) (2023)
Hedwig M Blommestein, Sonja Zweegman
Cost-effectiveness: maximizing impact by meticulous data. Blood 140 (6) (2022)
Yi Hsuan Chen, Dominique Molenaar, Carin A Uyl-de Groot, Marco van Vulpen, Hedwig M Blommestein
Medical Resource Use and Medical Costs for Radiotherapy-Related Adverse Effects: A Systematic Review. Cancers 14 (10) (2022)
Stefan Rabbe, Meilin Möllenkamp, Benedetta Pongiglione, Hedwig M Blommestein, Pim Wetzelaer, Renaud Heine, Jonas Schreyögg
Variation in the utilization of medical devices across Germany, Italy, and the Netherlands: A multilevel approach. Health economics (2022)
Maarten R Seefat, David G J Cucchi, Stijn Dirven, Kaz Groen, Sonja Zweegman, Hedwig M Blommestein
A Systematic Review of Cost-Effectiveness Analyses of Novel Agents in the Treatment of Multiple Myeloma. Cancers 13 (22) (2021)
Frederick W Thielen, Marie José Kersten, Pim Kuizenga, Mels Hoogendoorn, Eduardus F M Posthuma, Wendy Bc Stevens, Carin A Uyl-de Groot, Hedwig M Blommestein
Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view. Expert review of anticancer therapy 21 (12) (2021)